Edralbrutinib Drug Asset Due Diligence Report 2026

This Edralbrutinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Edralbrutinib can convert its Small molecule drug profile and BTK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Edralbrutinib (query alias: Edralbrutinib)
Modality / target	Small molecule drug; BTK; BTK inhibitors
Highest global status	Phase 2
Originator	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Active developers	Eternity Bioscience, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Reistone Biopharma Co. Ltd.

The MCP disease footprint includes Idiopathic Membranous Glomerulonephritis, B-cell lymphoma recurrent, Glomerulonephritis, Membranous. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05560360	Phase 1	Completed	20	Primary endpoint not disclosed in English source
NCT05136456	Phase 2	Active, not recruiting	61	Primary endpoint not disclosed in English source
NCT05095337	Phase 1	Unknown status	6	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

TG-1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B-CELL MALIGNANCIES

Phase 1; n=123; evaluation: Positive. Reported fields: Minor response = 4.3 % ; CR = 23.5 %

TG-1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND LYMPHOMA

Phase 1; n=123; evaluation: Not stated in English source. Reported fields: MTD(maximum tolerated dose) = not reached mg ; ORR(objective response rate) = 82.3 %

Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.

Phase 1; n=123; evaluation: Not stated in English source. Reported fields: TEAE = TEAEs leading to TG-1701 dose reduction occurred in 6.5% of pts. TEAEs leading to treatment discontinuation occurred in 1.6% of pts (AF, COVID-19)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Edralbrutinib addresses Idiopathic Membranous Glomerulonephritis, B-cell lymphoma recurrent, Glomerulonephritis, Membranous. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-01-08	Transaction title not available in English source	Not disclosed	US$1.0M upfront; US$173.1M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of BTK inhibitor for treating disease”. The milestone feed surfaced a patent-application signal described as “Preparation method of heteroaromatic ring BTK inhibitor intermediate”. The milestone feed surfaced a patent-application signal described as “Bruton's tyrosine kinase inhibitors as antiviral agents”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO